Subscribe to RSS
DOI: 10.1055/s-0031-1282823
Activity of (-) mammea A/BB from the Leaves of Calophyllum brasiliense on Mycobacterium tuberculosis
Despite the development of a number of effective treatments over the past half century, tuberculosis remains one of the most destructive bacterial infections in humans. The emergence of multidrug-resistant Mycobacterium tuberculosis leads to research of new classes of antimycobacterial agents (1). Calophyllum brasiliense Cambess (Clusiaceae) is a tree popularly known as „guanandi“ being a rich source of bioactive substances, including coumarins (2). Previous studies of (-) mammea A/BB reported leishmanicidal (3) and anti-HIV (4) activities. This compound is a coumarin-type mammea was purified from a dichloromethane crude extract of Calophyllum brasiliense leaves by chromatographic methods. In the current study, we evaluated the citotoxicity and in vitro antimycobacterial activity of the (-) mammea A/BB. The compound was identified by spectroscopic methods and comparison with literature data (5). Antimycobacterial activity determination was carried out using resazurin microtiter assay plate (REMA) to determine the minimum inhibitory concentration (MIC) (6) of (-) Mammea A/BB against M. tuberculosis H37Rv (ATCC 27294). The cytotoxicity assay was carried out by Sulforrhodamine B colorimetric method (7). The cytotoxicity for J774G8 macrophages was compared using the selectivity index (SI). The coumarin (-) mammea A/BB showed significant activity against M. tuberculosis with MIC value of 31,2µg/mL. The cytotoxicity against J774G8 macrophages showed SI of 0.823. These results provide new perspectives on the development of novel drugs obtained from natural products with anti M. tuberculosis activities.
Keywords: Calophyllum brasiliense, Mycobacterium tuberculosis, antimycobacterial
Acknowledgement: The authors are grateful to CNPq for providing a research grant and fellowships
References: 1. Luciani F et al. (2009) PNAS 106: 14711–14715. 2. Ito C (2002)J Nat Prod 65: 267–272. 3. Brenzan MA et al. (2008) Pharmaceutical Biology 46: 380–386. 4. Reyes-Chilpa R (2004) Life Sci 75: 1635–1647. 5. Brenzan MA et al. (2008) Biomedicine & Pharmacotherapy 62: 651–658. 6. Palomino J C et al. (2002) Antimicrob Agents Chemother 46: 2720–2722. 7. Papazisis KT (1997)J Immunol Methods 208: 151–158.